LENZ Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
LENZ Therapeutics R&D Spending Growth & History (LENZ)
LENZ Therapeutics's r&d spending was $18.7M for fiscal 2025.
View full LENZ Therapeutics company overviewLENZ Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.7M | −$11.1M | −37.35% |
| 2024 | 2024-12-31 | $29.8M | −$29.7M | −49.92% |
| 2023 | 2023-12-31 | $59.5M | −$13.3M | −18.25% |
| 2022 | 2022-12-31 | $72.8M | $34.9M | +91.89% |
| 2021 | 2021-12-31 | $37.9M | $28.8M | +315.78% |
| 2020 | 2020-12-31 | $9.1M | — | — |
LENZ Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$9.1M | — |
| Q1 2026 | 2026-03-31 | $0 | −$5.8M | — |
| Q4 2025 | 2025-12-31 | $0 | −$5.9M | — |
| Q3 2025 | 2025-09-30 | $3.8M | −$2.7M | −41.23% |
| Q2 2025 | 2025-06-30 | $9.1M | $2.1M | +30.47% |
| Q1 2025 | 2025-03-31 | $5.8M | −$4.7M | −44.79% |
| Q4 2024 | 2024-12-31 | $5.9M | −$13.7M | −69.96% |
| Q3 2024 | 2024-09-30 | $6.5M | −$10.6M | −62.06% |
| Q2 2024 | 2024-06-30 | $6.9M | −$5.7M | −45.05% |
| Q1 2024 | 2024-03-31 | $10.5M | $212,000 | +2.05% |
| Q4 2023 | 2023-12-31 | $19.5M | $1.1M | +5.82% |
| Q3 2023 | 2023-09-30 | $17.0M | −$1.3M | −7.09% |
| Q2 2023 | 2023-06-30 | $12.6M | −$5.1M | −28.90% |
| Q1 2023 | 2023-03-31 | $10.3M | −$7.9M | −43.41% |
| Q4 2022 | 2022-12-31 | $18.5M | $7.3M | +64.77% |
| Q3 2022 | 2022-09-30 | $18.3M | $9.6M | +110.78% |
| Q2 2022 | 2022-06-30 | $17.8M | $5.1M | +40.34% |
| Q1 2022 | 2022-03-31 | $18.2M | $12.9M | +239.33% |
| Q4 2021 | 2021-12-31 | $11.2M | — | — |
| Q3 2021 | 2021-09-30 | $8.7M | $6.4M | +275.89% |
| Q2 2021 | 2021-06-30 | $12.7M | $12.2M | +2894.56% |
| Q1 2021 | 2021-03-31 | $5.4M | — | — |
| Q3 2020 | 2020-09-30 | $2.3M | — | — |
| Q2 2020 | 2020-06-30 | $423,000 | — | — |
LENZ Therapeutics r&d spending trends
Over the last five fiscal years, LENZ Therapeutics's r&d spending increased from $9.1M to $18.7M, a change of $9.5M. The latest reported quarter, Q2 2026, shows $0.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review LENZ Therapeutics source filings ↗